The target concentration of remifentanil to suppress the hemodynamic response to endotracheal intubation during inhalational induction with desflurane.
10.4097/kjae.2011.60.1.12
- Author:
Jiwon LEE
1
;
Chul Woo JUNG
Author Information
1. Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Korea. spss@snuh.org
- Publication Type:Original Article
- Keywords:
Anesthesia;
Desflurane;
Inhalation;
Intravenous;
Remifentanil
- MeSH:
Androstanols;
Anesthesia;
Arterial Pressure;
Cough;
Heart Rate;
Hemodynamics;
Humans;
Inhalation;
Intubation;
Intubation, Intratracheal;
Isoflurane;
Isoxazoles;
Piperidines;
Unconscious (Psychology);
Unconsciousness
- From:Korean Journal of Anesthesiology
2011;60(1):12-18
- CountryRepublic of Korea
- Language:English
-
Abstract:
BACKGROUND: Anesthesia induction with desflurane is troublesome because of the frequent sympathetic hyperactivity during desflurane administration. We thought that a low concentration of desflurane combined with a target-controlled infusion (TCI) of remifentanil would eliminate the desflurane-related complications and provide hemodynamic stability during desflurane induction. An up-and-down study was planned to find the target effect-site concentration of remifentanil to block the hemodynamic response to endotracheal intubation, the highest level of stimulus, during anesthesia induction with administering desflurane at 1 MAC. METHODS: Remifentanil TCI was initiated before desflurane administration. When the preset target was achieved, spontaneous inhalation of desflurane 1 MAC was performed until the patients became unconscious. Laryngoscopic tracheal intubation was facilitated with rocuronium injection. The starting concentration of remifentanil and the test space were 5 and 1 ng/ml, respectively. The criteria for up-and-down was a 20% increase of the mean arterial pressure or heart rate after intubation. The median effective concentration (EC50) of remifentanil was calculated from 6 independent pairs. The complications related with remifentanil and desflurane were assessed during the study. RESULTS: We studied 20 patients using 2-5 ng/ml of the effect-site concentrations of remifentanil. The EC50 of remifentanil was 3.7 ng/ml. Loss of consciousness was achieved at 125 +/- 22 s after desflurane inhalation and this was irrespective of the combined remifentanil concentrations. Any remifentanil-related complication was not observed. Transient cough was seen in one patient who received 2 ng/ml of remifentanil. CONCLUSIONS: We demonstrated that uncomplicated induction with desflurane was possible by the use of target-controlled remifentanil. The EC50 of remifentanil to block the hemodynamic response to tracheal intubation was 3.7 ng/ml during inhalational induction with 1 MAC desflurane.
